Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes

Julia Feichtinger1, Ibrahim Aldeailej1,*, Rebecca Anderson1,*, Mikhlid Almutairi1, Ahmed Almatrafi1, Naif Alsiewiehri1, Keith Griffiths2, Nicholas Stuart1,3,5, Jane A. Wakeman1, Lee Larcombe4 and Ramsay J. McFarlane1,5

1 North West Cancer Research Fund Institute, Bangor University, Bangor, LL57 2UW, UK
2 Therapies and Health Sciences, Betsi Cadwaladr University Health Board, Bangor, LL57 2UW, UK
3 Medical Sciences, Bangor University, Bangor, LL57 2UW, UK
4 Bioinformatics Group, Cranfield Health, Cranfield University, Beds, MK43 0AL, UK
5 NISCHR Cancer Genetics Biomedical Research Unit

* These authors made an equal contribution

Correspondence to: Jane A. Wakeman/Ramsay J. McFarlane, e-mails: j.a.wakeman@bangor.ac.uk/r.macfarlane@bangor.ac.uk

Keywords: cancer biomarkers, cancer testes antigens, oncogenes, meiosis, PRDM9, cohesins drug targets

Received: July 26, 2012, Accepted: August 2, 2012, Published: August 13, 2012

Copyright: © Feichtinger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

ABSTRACT:

Identifying cancer-specific biomarkers represents an ongoing challenge to the development of novel cancer diagnostic, prognostic and therapeutic strategies. Cancer/testis (CT) genes are an important gene family with expression tightly restricted to the testis in normal individuals but which can also be activated in cancers. Here we develop a pipeline to identify new CT genes. We analysed and validated expression profiles of human meiotic genes in normal and cancerous tissue followed by meta-analyses of clinical data sets from a range of tumour types resulting in the identification of a large cohort of highly specific cancer biomarker genes, including the recombination hot spot activator PRDM9 and the meiotic cohesin genes SMC1beta and RAD21L. These genes not only provide excellent cancer biomarkers for diagnostics and prognostics, but may serve as oncogenes and have excellent drug targeting potential.

INTRODUCTION

The demarcation of neoplastic cells from healthy tissue represents an important goal in clinical oncology; this is of particular interest given the need for diagnostic markers to enable early intervention strategies, such as surgical resection, and the re-emergence of immunotherapeutics, cancer vaccines and targeted drug delivery via antibody-drug conjugates [1-10]. To achieve this goal, the identification of tumour-associated antigens is of central importance [for example, see 11-13]. Whilst almost all cancer cells have an altered gene expression profile, including many up regulated genes, most of the associated antigens are recognised as ‘self’ by the immune system, limiting their use in immune therapeutic, prognostic and diagnostic technologies. One family of proteins, the so-called cancer/testis (CT) antigens, represents an excellent group of cancer-specific biomarkers [14-21]. These are produced in the testes of healthy male adults and can also be found in cells with a cancerous phenotype. The immunological privilege of the testis [22,23] makes the CT antigens excellent immunological targets and a number of CT antigens have been employed successfully in a range of clinical applications, including adoptive therapeutics for late stage cancer treatment [for example, see 24]. Some CT antigens are also present in other immunologically privileged tissues of the central nervous
Many genes have been purported to encode CT antigens [21], however, not all of these have endured scrutiny and many of the genes have subsequently been found to have some degree of expression in normal somatic tissues [25]. This has lead to the redefining of CT genes into testis (and CNS)-restricted and testis (and CNS)-selective, where there is some evidence to indicate the latter class are expressed in at least one non-immune privileged, normal tissue type [25,26].

CT antigens have been further sub-classified into those which are encoded by genes on the X chromosome (X-CT genes) and those which are encoded by genes on autosomes (non-X-CT genes) [14-21]. The majority of characterised testis-restricted CT genes are X-CT genes and many of these reside within large families of orthologous genes, such as the MAGE family [14-21,27]. In addition, some CT genes are co-expressed in the same cancerous tissue, suggesting a dysfunction in one or more, as yet uncharacterised, testis-specific transcriptional regulatory pathway(s) [for example, see 28].

It has been demonstrated that some CT antigens have the potential for oncogenic activity or contribute to maintaining or enhancing the neoplastic state [19]. For example, MAGE-A2 has been demonstrated to induce the down regulation of one of the primary tumour suppressor genes, p53 [29]. Furthermore, MAGE-A2 and another MAGE family member, MAGE-A6, have been demonstrated to have the potential to induce resistance to chemotherapeutic agents [30]. However, the function, the oncogenic activity and the drug resistance-inducing potential of CT antigens remains poorly studied considering the potential importance of these proteins.

There has been speculation that some CT antigens could function in the testes to mediate the meiotic programme [31,32]. During meiosis the chromosomes of diploid progenitor cells (spermatogonia in testis) become reductionally segregated to produce haploid gametes (sperm cells in testis) [33,34]. This meiotic chromosome segregation involves a complex and poorly understood series of events, which include the pairing of homologous chromosomes followed by a covalent conjoining to generate a bivalent which is required for chromatid alignment at the first meiotic division. It has been postulated that the aberrant production of CT antigens with chromosome modulating potential in mitotically dividing somatic cells could result in inappropriate non-allelic inter-/intra-chromosomal recombination and interhomologue recombination events which could generate oncogenic genetic changes such as translocations and losses of heterozygocity [21,31,32]. In addition, the aberrant expression of meiotic chromosome regulators in matched induced pluripotent stem cells (iPSCs) has been demonstrated to illicit an immune response to iPSC-induced teratomas in mice indicating a broader importance to understanding the consequences of aberrant expression of meiotic genes [35].

In male mammals there exists a unique mechanism for the meiosis-specific transcriptional silencing of the X chromosome during the meiotic zygotene to pachytene transition, which is dependent upon meiotic double-strand break formation in unpaired chromatin [36]. This meiotic X inactivation suggests that most of the genes encoding known testis-restricted CT antigens are silenced during meiosis, as most of these are X-encoded and so may have largely non-meiotic roles in the testis.

These findings lead us to postulate that there is a family of human meiosis-specific genes, which are autosomally encoded and therefore not subjected to meiotic X inactivation. If these genes are aberrantly expressed in cancers and iPSCs they might represent a clinically important, novel sub-class of the testis-restricted CT gene family. Moreover, we speculated that such genes might have oncogenic activity by encoding proteins which interfere with chromosome dynamics and cell division when aberrantly expressed in mitotically dividing somatic cells. Here we identify human meiosis-specific genes showing the characteristics of CT genes, which we designate meiCT genes. This work defines a novel, meiosis-specific sub-class of clinically-relevant CT genes which includes previously uncharacterised human testis-specific genes, the human meiotic hotspot regulator gene PRDM9, the meiotic regulator gene STRA8 and meiosis-specific sister chromatid cohesion regulator gene.

**RESULTS**

**Analysis of selected meiotic chromosome regulatory genes for CT gene candidature**

Some important meiosis-specific genes which encode chromosome modulators have previously been reported to be CT genes, including SPO11 which encodes a meiosis-specific nuclease required for the initiation of meiotic recombination [15]; however, many of these previously identified meiotic regulators (including, SPO11, HORMAD1, SYCE1, SYCP1) have subsequently been found to be selective in their expression profile, suggesting they are not strictly testis-restricted [25]. As a first step to address the possibility that additional meiosis-specific genes might encode highly restricted CT antigens, we selected from the literature a sample cohort of human genes predicted to have meiosis-specific expression (Supplementary Table S1). These included genes encoding subunits of the meiosis-specific cohesin complex (REC8, STAG3, SMC1beta, RAD21L), which is responsible for modulating meiotic
recombination, meiotic centromere monopolarity and meiotic sister chromatid cohesion [37,38]. To assess the meiotic specificity of the selected genes, we obtained RNA extracted from a panel of normal human tissues, including testis, ovary and CNS tissue. We designed intron-spanning primer sets for the genes of interest and carried out reverse transcriptase polymerase chain reaction (RT-PCR) analysis as described in the materials and methods. Surprisingly, a number of these genes were expressed in a wide range of normal tissues, suggesting that their expression is not exclusively meiosis-specific (Fig. 1B; Supplementary Fig. S1A). These included two genes encoding cohesin components, *REC8* and *STAG3*, the protein products of which are widely accepted as being meiosis-specific from studies in other organisms, including the mouse [for example, 39]. Taking this further, we detected some expression of both *REC8* and *STAG3* in mouse non-meiotic somatic tissue using our RT-PCR conditions (Supplementary Fig. S1B), suggesting that expression of these genes is not fully restricted to meiosis, rather, they are subjected to a meiotic up regulation, consistent with previous analyses in the mouse [for example, 40]. DNA sequencing was used to confirm the identity of all RT-PCR products from both mouse and human. RT-PCR followed by DNA sequencing confirmed that a number of other genes we had postulated would be testis / meiosis-specific were expressed more extensively in non-meiotic tissues (Supplementary Fig. S1A; Supplementary Table S1). Despite the detection of *REC8* and *STAG3* expression in normal tissue, the other two meiosis cohesin genes tested, *RAD21L* and *SMC1-beta*, exhibited a tight testis-specific expression profile (Fig. 1A). To explore whether these testis-specific cohesin genes could potentially encode CT antigens we analysed their expression using RT-PCR on RNA samples taken from cancer cell lines and tumour samples from a range of cancer types. For both genes, expression was detected in a number of the cancer cells indicating they are CT genes (Fig. 1A). Of the other

---

**Figure 1:** Examples of gene expression and protein production profiles for predicted meiCT genes. A. Agarose gels showing RT-PCR profiles generated from a range of normal human tissues obtained post mortem (left two panels) and cDNA generated from a range of cancer cell lines or solid tumours (right hand two panels). The expression profile for *betaACT* is a positive control (top row). The profile for *SSX2* provides an example of a previously characterised X-CT gene. Five examples of testis-restricted meiCT genes are shown (*RAD21L/SMC1beta/PRDM9/C1orf65/STRA8*) along with the expression profile of one testis selective meiCT gene, *TEX19*. The *C5orf47* profile provides an example of genes which were testis-restricted with no evidence of expression in any of the cancer cells tested. B. Agarose gels showing RT-PCR profiles for normal human tissues for the mitotic cohesion gene *RAD21* and the two cohesin genes *REC8* and *STAG3*. C. Western blots showing the presence of the PRDM9 protein in the cancer cell line NTERA-2, but not in primary cultures of human prostate smooth muscle cells (HPrSMC).
manually selected genes a further five exhibited a CT gene expression profile (a mixture of cancer/testis-restricted and cancer/testis/CNS-restricted); these were the meiotic recombination hotspot activator gene PRDM9, the nuclear protein in testis (NUT) gene, the testis-specific serine/threonine kinase 1 (TSSK1) gene, the synaptonemal complex component gene SYCP1 (which has previously been reported as a CT gene [18]) and the meiotic regulatory gene STRA8 (Fig. 1A). A sixth gene, TEX19, exhibited a testis-selective expression profile as it was expressed in the testis and the thymus, the latter being a tissue known to undergo atrophy in older individuals such as those from which this tissue was derived, which may account for the expression of this gene in the thymus; TEX19 also exhibited extensive expression in many cancer types (Fig. 1A).

To address whether an expressed gene might be translated into a protein product, which might therefore provide an antigenic target in clinical applications, we carried out western blot analysis to detect the protein product of one of the CT genes identified above, PRDM9, for which commercial antibodies were available. The intracellular nature of these antigens does not preclude them from serving as targets for monoclonal antibody therapies or other immunotherapeutic approaches [for example, 24,41,42]. We generated whole cell extracts (WCEs) from one of the cancer cell lines in which PRDM9 gene expression had been observed, NTERA-2 (Fig. 1A), and a culture of non-cancerous primary human prostate smooth muscle (HPrSM) cells, in which no PRDM9 gene expression could be detected by RT-PCR. PRDM9 was readily detectable in the cancer cells, but not in the HPrSM cells (Fig. 1C) demonstrating that the expression of the PRDM9 CT gene results in protein production, leading to the possibility that the de-repression of the PRDM9 gene generates a protein which could be antigenic and thus be of clinical and oncogenic importance.

Identification and validation of novel meiosis-associated CT genes using computational analysis of EST data

Whilst the above approach has identified a number of new CT genes, it is limited by the fact that a manual curation of the literature is not only time-consuming, but also exposes relatively few mammalian meiosis-specific genes. We took advantage of a previous large scale microarray study which identified 744 mouse meiosis-specific genes [43]. After human orthologue assignment and filtering to eliminate non-testis-specific genes, 375 human genes remained and these were fed into an expressed sequence tag (EST) analysis pipeline based on the complete Unigene database (Fig. 2; support text to Fig. 2 is given in Supplementary Information).
Supplementary Information). Briefly, if a candidate gene is represented in a non-testis / non-CNS normal tissue EST library, it was dismissed. The remaining genes were further assessed for representation in cancer EST libraries. This screen identified 177 candidate genes, of which 9 were cancer/testis-restricted (class 1), 75 were testis-restricted (class 2), 21 were cancer/testis/CNS-restricted (class 3) and 72 were testis/CNS-restricted (class 4). We favoured an EST screen, since microarray technology is limited by the number of published cancer arrays available as well as by the number of genes which can be analysed due to lack of gene coverage on arrays. Moreover, an EST screen can confirm the testis-restricted expression pattern and therefore functions as an additional filter to eliminate non-testis-restricted genes. However, microarray data sets were not ignored and following experimental validation of the candidates (see below) we carried out meta-analysis of clinically-relevant cancer microarray data sets (see below).

Having identified candidates in the four classes outlined above we validated those in classes 1-3 using RT-PCR. We included the genes in class 2, which are predicted to be testis-specific, but have not been identified in the EST data sets of cancer tissue. We initially carried out RT-PCR on RNA isolated from a range of normal human tissues, including testis-derived RNA, as described above. Of the 105 genes in classes 1-3 we could not obtain RT-PCR products in our control tissue (testis) for 12 genes, resulting in 93 genes which were subjected to RT-PCR validation. Of these, 39 genes were expressed in more than two non-testis/CNS normal tissues and were therefore dismissed at this stage. Of the remaining 54 genes, 41 had expression restricted to testis in normal tissues, 3 had expression restricted to testis and CNS tissue and 10 were testis-specific, or testis/CNS-specific and yet exhibited expression in one or two normal tissues. RT-PCR analysis was carried out to assess the expression profiles of these 54 genes in cancer cells, as above. From these analyses it was determined that 29 genes exhibited no expression in any of the cancerous material and appeared to be tightly testis-specific (Supplementary Table S2; the example of C5orf47 is shown in Fig. 1A); 12 were CT-restricted genes and they were expressed in the testis and at least one cancer type (the example of C1orf65 is shown in Fig. 1A; Fig. 3); 3 were cancer/testis/CNS-restricted genes as they were expressed in testis, CNS and at least one cancer type (Fig. 3); 6 were cancer/testis-selective as they were expressed in testis, one or two other non-testis/CNS normal tissues and at least one cancer type (Fig. 3); 4 were cancer/testis/CNS-selective as they were expressed in testis, CNS tissue, one or two other normal tissue types and at least one cancer type (Fig. 3). This resulted in the identification of a total of 25 genes distributed in the various CT classes. This, in combination with the 8 CT genes identified in the preliminary study (see above) resulted in the identification of 33 restricted / selective CT or CT/CNS genes, most of which have not been previously characterised as CT genes and are largely autosomally encoded; we will refer to these as meiCT genes (Fig. 3).

**Meta-analysis of validated candidate genes**

To explore the clinical relevance of the 33 meiCT genes we have identified, we developed a meta-analysis pipeline for patient-derived cancer microarray data including 13 cancer types (Fig. 2; support text to Fig. 2 is given in Supplementary Information; Supplementary Table S3). We analysed the meta-change in gene expression of patient-derived, untreated cancerous tissues compared to normal tissues for the candidates as well as for 3 known X-CT control genes (MAGE-A1, GAGE, SSX2) in a total of 80 microarray data sets (Supplementary Table S3). Of the 33 candidates, 25 were covered by the array sets and could be evaluated (Supplementary Table S4). This revealed that 15 of the meiCT genes exhibited statistically significant, cancer-specific mean up regulation in at least one cancer type for combined data sets for specific cancer types where enough clinically-derived data sets were available (Fig. 4; Supplementary Table S4). The Circos plot (Fig. 4) shows the meta-change in gene expression in relation to the corresponding cancer type. This provides evidence that the meiCT genes are expressed in clinically-relevant material and shows examples of more extensive tumour expression patterns. Some notable patterns emerge from these analyses; firstly, many of the meiCT genes show a mean up regulation in ovarian, brain and lung cancers; secondly, a number of cancer types exhibit no mean up regulation of any of the analysed meiCT genes, these include breast and colorectal, for which 11 and 13 microarray data sets were available. However, a limited number of microarray data sets were available for many cancer types and thus designating cancer specificity from these data has limitations.

Whilst a significant mean up regulation is observed for a number of genes in combined data sets for distinct cancer types (Fig. 4), this does not reflect a uniform up regulation of a specific gene in all samples for a given cancer type. For example, PRDM9 exhibits a significant mean up regulation in the ovarian cancer microarray sets used (Fig. 4); however, it is not significantly up regulated in all the individual cancer samples tested, despite the significant mean elevation (Fig. 5). This indicates that these markers may not be universally up regulated in specific cancer sub-types or cancer samples. Extending this, we determined that a further number of clinically-derived cancer samples exhibited up regulation of a wider range of
the 25 meiCT genes represented on the arrays in individual (not combined) cancer data sets (cancer vs. normal) (Supplementary Fig. S2A) indicating the meiCT genes are expressed in clinically-relevant samples covering a broad range of cancer types.

The meta-analysis approach was extended to address whether any of the 29 genes ascribed as testis-specific (no evidence for expression in any of the cancer cells we tested) by RT-PCR analysis, were up regulated in the clinically-derived microarray data sets. Of the 29 genes, 21 were represented on the arrays (Supplementary Table S2). Meta-analysis of combined cancer data sets revealed that 9 of these genes showed a significant mean up regulation in leukaemias and lung and ovarian cancers (Fig. 6). These findings indicate that these further 9 genes qualify as meiCT genes, bringing the total number of meiCT genes identified in this study to 42 (Supplementary Table S5), many of which are novel genes which have not been classified as cancer biomarkers. Additionally, analysis of individual (not combined) cancer data sets revealed up regulation of 19 of the 21 genes in a broader range of cancer types (Supplementary Fig. S2B), indicating that a further 10 genes could be considered as meiCT genes.

Figure 3: Grid representation of gene expression profiles for the 33 meiCT genes identified. Each gene has a lane allocation on the grid; the presence of a blue square within any column in a given lane represents the presence of an RT-PCR product indicating gene expression. The shade of blue is a qualitative representation of the RT-PCR product intensity on agarose gels. The meiCT genes have been separated into distinct classes based on those of Hofmann et al. [25]: A. Examples of known X-CT genes (positive controls); B. Testis-restricted meiCT genes (17 genes); C. Testis/CNS-restricted meiCT genes (5 genes); D. Testis-selective meiCT genes (7 genes); E. Testis/CNS-selective meiCT genes (4 genes). The chromosomal location of all genes is given following the gene name. Genes marked with an asterisk are genes we identified which have previously reported as CT genes [15].
DISCUSSION

The restricted regulation of CT genes has resulted in the emergence of their associated antigens as important oncological biomarkers. However, the classification of CT genes remains fraught with difficulties and it has been proposed that a uniform classification is premature until a greater insight into the biology and clinical importance of CT genes is revealed [25]. Here we add a new group of genes to this expanding family, the meiCT genes, which not only have expression restricted to the testis, but are likely to be further restricted to the highly immunologically privileged meiotic spermatocytes. These are more widely represented on the autosomes than previously characterised CT genes (45 of the 52 meiCT genes are autosomally encoded; Supplementary Table S5) and their identification opens up new possibilities in terms of both tumour distribution and oncogenic activities. Analysis of the meiCT genes demonstrates that these are expressed in a wide range of cancer types. For example, our RT-PCR validation demonstrates expression of a number of meiCT genes, including PRDM9, in lymphoma and leukaemia lines (Fig. 1A; Fig. 3). Of the 46 genes subjected to meta-analysis (combined cancer data sets), 20 were expressed in ovarian cancers. The use of CT antigens for immunotherapies to treat ovarian cancers...
has yielded positive results (for example, see 44), and so
the finding that the meiCT genes are extensively
expressed in ovarian cancers could provide an addi-
tional suite of markers for a tumour type which is
amenable to immunotherapeutic approaches. In addi-
tion to the meta-analysis, study of individual cancer
data sets (cancer vs. normal) suggested expression of
additional meiCT genes (42 out of the 44 represented
on microarrays) in a broader range of cancer sub-types
(Fig. 6; Supplementary Fig. S2; Supplementary Table
S5); however, the extent to which these single data set
analyses reflect extensive expression in a given cancer
type will rely on the generation of further clinically-
derived data sets and their subsequent analyses,
whereas meta-analyses are generally accepted to indi-
cate a more precise and reliable estimate of gene expres-
sion for a given cancer type.

In our original computational analysis we applied
relatively stringent conditions to the classification of
the meiCT genes. We only selected candidates for valida-
tion which were not represented in EST libraries of any
non-testis / non-CNS normal tissue types. Chen and
co-workers [26] challenged EST data sets with testis-
specific genes identified by massive parallel sequencing
and retained those genes with expression in one or two
other non-testis normal tissues. Indeed, when we re-ran
our analysis setting the criteria with this same lower
stringency we identified a significant number of addi-
tional candidates. We took the more stringent approach
so as to target meiCT genes which were tightly restricted
CT genes. However, on validation we revealed a number
of meiCT genes which fall into the CT (and CT/CNS)
selective class. This might be due to the nature of the
so-called normal tissue; as in our case, RNA from
many normal tissues are extracted from tissue obtained
post mortem and are often pooled from tissues from a
number of individuals, many of whom were aged at time
of death. It remains a possibility that some of these
tissues had undergone undiagnosed neoplastic change
and might have been aberrantly expressing one or more
of the candidate genes. In support of this, Chen and
co-workers [26] observed expression of some genes in
tissues from one panel of normal tissues, but detected
no measurable expression in similar tissue types from a
distinct second source. Thus, genes which exhibit meiCT
selective profiles, such as TEX19, might indeed be CT
restricted genes and be of clinical use.

Meiotic chromosome regulators as CT genes

Here we have identified a number of previously
uncharacterised genes as meiCT genes; for example,
C12orf12. However, we also find that a number of
relatively well characterised meiotic genes are meiCT
genotypes. It has been previously proposed that the aber-
rant expression of CT genes may have an oncogenic
effect [18,32] and indeed, aberrant expression of germ
line genes in Drosophila contributes to malignant
growth [45]; when this idea is applied to the genes
identified here it opens up some interesting possibili-
ties, which might indicate that the meiCT genes might
not only be oncogenic, but might also provide drug
targeting opportunities. For example, the meiotic
cohesin genes RAD21L and SMC1beta may produce
proteins which are incorporated into functional cohe-
sin complexes within mitotically dividing tissues; this
may not only result in aberrant modulation of chro-
mosome segregation resulting in genome instability,
but might also provide a cancer cell-specific drug tar-
get to inhibit chromosome segregation.

The expression of the meiotic recombination
hotspot activator gene PRDM9 is intriguing as the
gene product is a sequence-specific zinc finger histone
methyltransferase known to regulate the epigenetic
programme for hotspot chromatin activation [46,47]
and in mice the orthologue, Meisetz, has a function
in transcriptional regulation where it activates expres-
sion of the testis-specific RIK gene, amongst others
[48]. We could find no evidence that any of the human
orthologues of RIK were differentially activated in
cancer cells expressing PRDM9, but the possibility
remains that active PRDM9 protein in somatic cells
might trigger unscheduled transcriptional activity and/
or generate regions with altered chromatin structure
which could form unstable chromatin lesions, both of
which could be oncogenic in nature.

In addition to identifying the meiCT genes, we
found expression in non-testis tissues of a number of
genotypes which are reported as meiosis-specific, including
REC8 and STAG3. This is not inconsistent with pre-
vious studies, where these genes are reported to be up
regulated in the testis and are not testis-restricted.
Why might some genes, which encode meiosis-specific
functions, be less tightly regulated than others? The
answer to this could come from studies in the fission
yeast were the production of Rec8 protein in mitotic
cells is inhibited by specific post-transcriptional mRNA
degradation [49,50]. If an analogous system were oper-
ating in mammals then many CT antigen genes might
be missed using transcriptional profiling alone; REC8
and STAG3 might prove to be good genes on which
to test this idea. This raises the possiblity that CT anti-
gens can be generated not only by transcriptional dys-
function, but also by the de-regulation of translational
repression programmes which ensure spermatocyte-/
-testis-specific translation.

Conclusions

Here we have characterised a sub-class of a clini-
cally-important family of genes and identified a large
number of previously unclassified/uncharacterised genes
as potential clinically-relevant cancer biomarkers. Their identification also exposes a new cohort of genes which might have oncogenic characteristics, whose protein products might not only serve as targets for immune therapeutics, but also as new drug targets and oncogenic drivers.

MATERIALS AND METHODS

Cell lines and cell culture

The NTERA-2 (clone D1) cell line was gifted by Prof. P.W. Andrews (University of Sheffield) and are regularly authenticated within the group using standard antibody tests using anti-OCT4 antibodies and retinoic acid-induced differentiation. The A2780 cell line was provided by Prof. P. Workman (Cancer Research UK Centre for Cancer Therapeutics, Surrey, UK) and was authenticated at source. The following cell lines were purchased from the European Collection of Cell Cultures (ECACC); 1321N1, COLO800, COLO857, G-361, HCT116, HT29, LoVo, MM127, SW480 and T84. H460 was purchased from the American Type Culture Collection (ATCC), and the two ovarian adenocarcinoma cell lines, PEO14 and TO14, were obtained from Cancer Research Technology Ltd. Primary cultures of proliferating human prostate smooth muscle cells were obtained from PromoCell™ (C-12574). All cultures were used within a six month period of obtaining validated lines from external sources.

1321N1, A2780, NTERA-2 (clone D1) and SW480 cell lines were cultured in Invitrogen Dubeco’s modified Eagle’s medium (DMEM + GLUTAMAX™) supplemented with 10% foetal bovine serum (FBS), COLO800, COLO857 and H460 cell lines were cultured in Invitrogen Roswell Park Memorial Institute 1640 medium (RPMI 1640) + GLUTAMAX™ with 10% FBS. PEO14 and TO14 cell lines were cultured in RPMI 1640 + GLUTAMAX™ supplemented with 10% FBS and 2 mM sodium pyruvate, and MM127 was cultured in RPMI 1640 + GLUTAMAX™ supplemented with 10% FBS and 25 mM HEPES. Invitrogens McCoy’s 5A medium + GLUTAMAX™ supplemented with 10% FBS was used to culture the G-361, HCT116 and HT29 cell lines. Ham’s F12 + DMEM (1:1) + GLUTAMAX™ (Invitrogen™) with 10% FBS was used to culture T84 cells.

All cell lines were grown in a 37°C incubator with 5% CO2, with the exception of the NTERA-2 (clone D1) cell line which was grown at 37°C with 10% CO2.

cDNA construction

Total RNA preparations from the human and mouse normal tissue panels (Clontech™; 636643 and 636745 respectively). RNA from tumour tissues and cell lines were purchased from Clontech™ and Ambion™. Total RNA was also isolated from cells using TRIzol (Invitrogen). Confluent cells were collected in TRIzol reagent and incubated at room temperature for 5 minutes. Chloroform was added with vigorous shaking and incubated for 5 minutes at room temperature. The aqueous phase was transferred to a clean tube following centrifugation at 12,000 g for 15 minutes at 4°C. The RNA was precipitated out of solution using isopropanol (10 minutes at room temperature and centrifuged at 12,000 g for 20 minutes at 4°C). RNA preparations were re-suspended in RNase-free water containing DNase. The concentration and quality of RNA was measured using a NanoDrop (ND_1000). 1.0 µg of total RNA was reverse-transcribed into cDNA using SuperScript III First Strand synthesis kit (Invitrogen™) as per the manufacturer’s instructions.

RT-PCR

The sequences for each of the genes analysed were obtained from the National Center for Biotechnology (NCBI; http://www.ncbi.nlm.nih.gov/). Primers to each of the genes were designed to span exons where possible using Primer3 software (available from: www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi; primer sequences are available upon request).

A volume of 2 µL diluted cDNA (containing ~150 ng/µl cDNA) was used for PCR in a 50 µL final volume. BioMix™ Red (Bioline™) was used for PCR amplification. Samples were amplified with a pre-cycling hold at 96°C for 5 minutes, followed by 40 cycles of denaturing at 96°C for 30 seconds, annealing at a temperature between 58-62°C for 30 seconds and extension at 72°C for 40 seconds followed by a final extension step at 72°C for 5 minutes. The products were separated on 1% agarose gels containing ethidium bromide.

Western blot analysis

Whole cell protein lysates were prepared from cells using lysis buffer {50 mM Tris-HCl pH7.4, 200 mM sodium chloride, 0.5% Triton X-100, 1 mM AEBSF [4-(2-aminoethyl)benzenesulfonyl fluoride] with complete, EDTA-free protease inhibitor cocktail (Roche)} and Laemml buffer. The samples were boiled and an aliquot containing 60,000 cells was subjected to denaturing gel electrophoresis using a NuPAGE™ 4-12% Bis-Tris gel (Invitrogen™) and transferred to a PVDF membrane (Millipore™). Membranes were blocked for one hour using 1xPBST (0.3% Tween-20) containing 5% non-fat dry milk, followed by an overnight incubation at 4°C with rabbit polyclonal anti-PRDM9 antibody (Abcam; ab85654) at a dilution of 1:1,000, or mouse monoclonal anti-tubulin antibody (Sigma cat. no. T6074) at a
dilution of 1:5,000, or goat polyclonal anti-lamin antibody (Santa Cruz cat. no. sc-6217) at a dilution of 1:1,000. Membranes were washed using 1xPBST and incubated with either goat, mouse or rabbit HRP-conjugated IgG antibody dependent upon the primary antibody. ECL detection reagents were then used for visualisation (SuperSignal West Pico Chemiluminescent Substrate; Thermo Scientific).

ACKNOWLEDGEMENTS

JF was supported by the National Institute of Social Care and Health Research (grant HS/09/008). IA, MA, AA, NA were supported by the Saudi Arabia Government. RA was supported by a Knowledge Economy Skills Scholarship (Welsh Government’s European Science Foundation convergence programme)/UK NHS. RJM/JAW were supported by Cancer Research Wales. RJM is supported by the North West Cancer Research Fund (project grant CR888).

Editorial note: This paper was accepted based in part on peer-review in another journal (in addition to peer-review in Oncotarget).

CONFLICT OF INTERESTS

There are no conflicts of interests to declare.

REFERENCES

1. Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines. 2011; 10: 1281-1289.

2. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? ImmunoI Rev. 2011; 239: 27-44.

3. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy—revisited. Nat Rev Drug Discov. 2011; 10: 591-600.

4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480: 480-489.

5. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011; 186: 1325-1331.

6. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulation therapy. Cancer J. 2011; 17: 372-378.

7. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know. Nat Rev Clin Oncol. 2011; 8: 577-585.

8. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011; 29: 4828-4836.

9. Tuma RS. Enthusiasm for antibody-drug conjugates. J Natl Cancer Inst. 2011; 103: 1493-1494.

10. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012; 148: 1081-1084.

11. Straten P, Andersen MH. The anti-apoptotic members of the Bcl-2 family are attractive tumour associated antigens. Oncotarget 2010; 1: 239-245.

12. Scrimieri F, Calhoun ES, Patel K, Gupta R, Huso RH, Kern SE. FAM190A rearrangements provide a multitude of individualized tumour signatures and neo-antigens in cancer. Oncotarget 2011; 2: 69-75.

13. Ionov Y. A high throughput method for identifying personalized tumour-associated antigens. Oncotarget 2010; 1: 148-155.

14. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells. 2007; 25: 707-711.

15. Almeida LG, Sakabe NJ, de Oliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Junghluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, et al. CT database: a knowledge-base of high throughput and curated data on cancer/testis antigens. Nucleic Acids Res. 2009; 37: D816-819.

16. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009; 100: 2014-2021.

17. Cheng YH, Wong EW, Cheng CY. Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 2011; 1: 209-220.

18. Fratta E, Coral S, Covre A, Parigi G, Colizzi F, Danielli R, Marie Nicolay HJ, Sigalotti L, Maio M. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011; 5: 164-182.

19. Mirandola L, Cannon M, Cobos E, Bernardini G, Jenkins MR, Kast WM, Chiriva-Internati M. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol. 2011; 30: 127-137.

20. Lim SH, Zhang Y, Zhang J. Cancer-testis antigens: the current status on antigen regulation and potential clinical use. Am J Blood Res. 2012; 2: 29-35.

21. Simpson AJ, Caballero OL, Junghluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5: 615-625.

22. Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev. 2006; 213: 66-81.

23. Mruk DD, Cheng CY. Tight junctions in the testis: new perspectives. Philos Trans R Soc Lon B Sci. 2010; 365: 1621-1635.

24. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Junghluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Eng J Med. 2008; 358: 2698-2703.
25. Hofmann O, Cabellero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carminci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 2008; 105: 20422-20427.
26. Chen YT, Scanlan MI, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vaseck T, Straubsg RL, Jongeneel CV, Old LJ, Simpson AJ. Identification of cancer/testis-antigen genes by massive parallel signature sequencing. Proc Natl Acad Sci USA. 2005; 102: 7940-7945.
27. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001; 61: 5544-5551.
28. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA. 2009; 106: 13493-13498.
29. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C. MAGE-A tumour antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 2006; 103: 11160-11165.
30. Duan Z, Duan Y, Lamendola DE, Yusurf RZ, Naeem R, Penson RT, Seiden MV. Over expression of MAGE/GAGE genes in paxiltaex/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003; 9: 2778-2785.
31. Chalmel F, Lardenois A, Primig M. Toward understanding the core meiotic transcriptome in mammals and its implications for somatic cancer. Ann N Y Acad Sci. 2007; 1120: 1-15.
32. Wang J, Emadali A, Le Bescont A, Callanan M, Rousseaux S, Khochbin S. Induced malignant genome reprogramming in somatic cells by testis-specific factor. Biochim Biophys Acta. 2011; 1809: 221-225.
33. Yanowitz J. Meiosis: making a break for it. Curr Opin Cell Biol. 2010; 22: 744-751.
34. Zickler D, Kleckner N. Meiotic chromosomes: integrating structure and function. Annu Rev Genet. 1999; 33: 603-754.
35. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474: 212-215.
36. Turner JM. Meiotic sex chromosome inactivation. Development. 2007; 134: 1823-1831.
37. Jessberger R. Cohesin complexes get more complex: the novel kleisin RAD21L. Cell Cycle. 2011; 10: 2053-2054.
38. Uhlmann F. Cohesin subunit Rad21L, the new kid on the block has new ideas. EMBO Rep. 2011; 12: 183-184.
39. Ishiguro K, Kim J, Fujiyama-Nakamura S, Kato S, Watanabe Y. A new meiosis-specific cohesion complex implicated in the cohesion code for homologous pairing. EMBO Rep. 2011; 12: 267-275.
40. Lee J, Hirano T. RAD21L, a novel cohesion subunit implicated in linking homologous chromosomes in mammalian meiosis. J Cell Biol. 2011; 192: 263-276.
41. Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnajtic S, Ritter G, Sakauchi S, Old LJ, Shiku H, Nishikawa H. Intracellular tumour-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 2012; 72: 1672-1682.
42. Guo K, Tang JP, Tan CPB, Hong CW, Al-Aidaroos AQO, Varghese L, Huang C, Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011; 3: ra85.
43. Chalmel F, Rolland AD, Niederhauser-Wiederkehr C, Chung SS, Demougin P, Gattiker A, Moore J, Patard JJ, Wolgemuth DJ, Jéquou B, Primig M. The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci USA. 2007; 104: 8346-8351.
44. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffmann EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnajtic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA. 2007; 104: 12837-12842.
45. Janic A, Mendizabal L, Llamazares S, Rosell D, Gonzalez C. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Nature. 2010; 330: 1824-1827.
46. Hochwagen A, Marais GA. Meiosis: a PRDM9 guide to the hotspot of recombination. Curr Biol. 2010; 20: R271-R274.
47. McVean G, Myers S. PRDM9 marks the spot. Nat Genet. 2010; 42: 821-822.
48. Hayashi K, Yoshida K, Matsui Y. A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. Nature. 2005; 438: 374-378.
49. Harigaya Y, Tanaka H, Yamanaka S, Tanaka K, Watanabe Y, Tsutsumi C, Chikashige Y, Hiraoka Y, Yamashita A, Tamamoto M. Selective elimination of messenger RNA prevents an incidence of untimely meiosis. Nature. 2006; 442: 45-50.
50. Hiriiart E, Vavasseur A, Touat-Todeschini L, Yamashita A, Gilquin B, Lambert E, Perot J, Shichino Y, Nazaret N, Boyault C, Lachuer J, Peraza D, Yamamoto M, Verdel A. MmiRNA surveillance machinery directs RNAi complex RITS to specific meiotic genes in fission yeast. EMBO J. 2012; 31: 2296-2308.